胆固醇
胆结石
内科学
非酒精性脂肪肝
内分泌学
医学
新陈代谢
脂质代谢
肝X受体
脂肪肝
疾病
生物
生物化学
基因
核受体
转录因子
作者
Chenghao Zhang,Wanlin Dai,Shaojie Yang,Shuodong Wu,Jing Kong
标识
DOI:10.1210/clinem/dgad528
摘要
Abstract Cholesterol gallstone disease (CGD) is one of the most common digestive diseases, and it is closely associated with hepatic cholesterol metabolism. Cholesterol gallstones may be caused by abnormal hepatic cholesterol metabolism, such as excessive cholesterol biosynthesis within the liver, interfering with the uptake or export of cholesterol in the liver, and abnormal hepatic cholesterol esterification. In this review, we begin with a brief overview of the clinical diagnosis and treatment of gallstone disease (GSD). Then, we briefly describe the major processes of hepatic cholesterol metabolism and summarize the key molecular expression changes of hepatic cholesterol metabolism in patients with gallstones. We review and analyze the recent advances in elucidating the relationships between these key molecules and CGD, and some targets significantly impacting on CGD via hepatic cholesterol metabolism are also listed. We also provide a significant discussion on the relationship between CGD and nonalcoholic fatty liver disease (NAFLD). Finally, the new discoveries of some therapeutic strategies associated with hepatic cholesterol metabolism to prevent and treat CGD are summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI